The gene encoding the cyclin-dependent kinase inhibitor 2A (CDKN2A) is frequently lost or mutated in 40-70% of sporadic melanoma tumors, and 20-40% of familial melanomas (10). This evidence concerns the gene CDKN2A and melanoma.